,address1,address2,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,1100 Massachusetts Avenue,Floor 4,Cambridge,MA,02138,United States,(617) 453-1000,(617) 453-1001,https://www.infi.com,Biotechnology,Healthcare,"Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.",30,"{'maxAge': 1, 'name': 'Dr. Lawrence E. Bloch J.D., M.D.', 'age': 56, 'title': 'Treasurer', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 513610, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.0843,0.0745,0.0333,0.08,0.0843,0.0745,0.0333,0.08,0.0,1.380359,-0.08127273,21379097,21379097,3958883,4285280,4285280,0.0,0.0,800,1000,4057021,0.02,1.33,1.5792218,0.1252,0.28475,0.0,0.0,USD,-14744136,0.0,81905522,90761104,2206146,918879,1690761600,1693440000,0.024300002,0.023559999,0.23485,0.31,0.0247,-0.412,1672444800,1703980800,1688083200,-40948000,-0.37,-0.55,1:4,1158105600,-5.739,0.369,NMS,EQUITY,INFI,INFI,"Infinity Pharmaceuticals, Inc.","Infinity Pharmaceuticals, Inc.",964791000,America/New_York,EDT,-14400000,0.0447,0.3,0.3,0.3,0.3,3.0,hold,1,17746000,0.196,-39918000,633000,1.471,1.65,2569000,0.029,-0.60697,-31381000,-21811750,-38884000,-0.15,0.0,0.0,-15.70494,USD,
1,1100 Massachusetts Avenue,Floor 4,Cambridge,MA,02138,United States,(617) 453-1000,(617) 453-1001,https://www.infi.com,Biotechnology,Healthcare,"Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.",30,"{'maxAge': 1, 'name': 'Mr. Seth A. Tasker J.D.', 'age': 43, 'title': 'CEO, Sr. VP, Gen. Counsel & Sec.', 'yearBorn': 1979, 'fiscalYear': 2020, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.0843,0.0745,0.0333,0.08,0.0843,0.0745,0.0333,0.08,0.0,1.380359,-0.08127273,21379097,21379097,3958883,4285280,4285280,0.0,0.0,800,1000,4057021,0.02,1.33,1.5792218,0.1252,0.28475,0.0,0.0,USD,-14744136,0.0,81905522,90761104,2206146,918879,1690761600,1693440000,0.024300002,0.023559999,0.23485,0.31,0.0247,-0.412,1672444800,1703980800,1688083200,-40948000,-0.37,-0.55,1:4,1158105600,-5.739,0.369,NMS,EQUITY,INFI,INFI,"Infinity Pharmaceuticals, Inc.","Infinity Pharmaceuticals, Inc.",964791000,America/New_York,EDT,-14400000,0.0447,0.3,0.3,0.3,0.3,3.0,hold,1,17746000,0.196,-39918000,633000,1.471,1.65,2569000,0.029,-0.60697,-31381000,-21811750,-38884000,-0.15,0.0,0.0,-15.70494,USD,
